A Study of First Line Treatment With Tarceva (Erlotinib) in Combination With Gemcitabine in Patients With Locally Advanced Unresectable or Metastatic Pancreatic Cancer

NCT00642733 · clinicaltrials.gov ↗

PHASE4

Phase

TERMINATED

Status

6

Enrollment

INDUSTRY

Sponsor class

Stopped poor recruitment

Conditions

Pancreatic Cancer

Interventions

DRUG: erlotinib [Tarceva]
DRUG: gemcitabine

Sponsor

Hoffmann-La Roche